BRAINAURORA-B (06681) announced that the company recently signed important business cooperation agreements with Peking University Sixth Hospital and Shandong Mental Health Center (collectively referred to as the "Cooperative Partners") to jointly advance the research, development, and commercialization of digital therapeutic products for mental health. Furthermore, the "Beijing Key Laboratory for Innovative Translation of Precision Intelligent Diagnosis and Treatment for Mental Disorders," jointly applied for by the company, Peking University Sixth Hospital, and the National Engineering Research Center for Software Engineering at Peking University, has been officially approved for establishment. The joint R&D with Peking University Sixth Hospital includes the development of digital therapies and clinical application research, studies on the efficacy of cognitive digital therapy for Attention Deficit Hyperactivity Disorder (ADHD), and a precision intelligent diagnosis and treatment system for depression. The research scope encompasses developing and clinically validating digital therapeutic products for emotional and behavioral issues from a full-lifecycle perspective, including studies on the efficacy and compliance of cognitive digital therapy for improving the learning abilities of children with ADHD, the development and efficacy research of a digital collaborative intervention therapy for emotional disorders in children and adolescents involving "home-school-medical" components, the R&D and clinical validation of cognitive digital therapy products for adult ADHD, the development and clinical research of ADHD coaching courses and digital products, the development of multimodal diagnostic technologies for depression, the development of a stratified intervention system based on the severity of depression, and the construction of a precise, accessible, and safe stepped-care intervention platform for depression to provide digital therapeutic solutions. It will further optimize computerized cognitive assessment and intervention tasks along with personalized recommendation algorithms to enhance targeted cognitive digital therapies. The collaboration on digital technical services for cognitive disorder diagnosis and treatment aims to jointly establish a diagnostic, treatment, and health management system covering the elderly, children, and adults for cognitive disorders. The joint R&D with Shandong Mental Health Center focuses on cognitive screening and intervention systems related to mental disorders, containment capacity training methods and systems guided by virtual humans, and subsequently conducting research on mentalization treatment methods and systems based on virtual humans and large language models. Collaboration on digital technical services for cognitive disorder diagnosis and treatment aims to jointly establish a diagnostic, treatment, and health management system covering the elderly, children, and adults for cognitive disorders. As a core co-construction unit, the company, together with Peking University Sixth Hospital and the National Engineering Research Center for Software Engineering at Peking University, has officially received approval to establish the "Beijing Key Laboratory for Innovative Translation of Precision Intelligent Diagnosis and Treatment for Mental Disorders." The laboratory will focus on collaborative efforts for innovation and translation driven by the clinical needs of mental and psychological diseases, bringing together多方力量 from clinical medicine, basic research, technology development, and hardware innovation to form a synergistic R&D model characterized by "clinical drive, basic support, software-hardware integration, and贯通转化." The company will be primarily responsible for the core technology R&D, productization, and user experience optimization in the direction of innovative translation for precision intelligent diagnosis and treatment of mental disorders, further consolidating the Group's technological leadership in the field of mental health digital therapies. To date, the company has established close commercial cooperation with Beijing Anding Hospital, affiliated with Capital Medical University (a Grade III, Level A psychiatric specialist hospital and the National Center for Mental Diseases), to jointly promote the clinical application of mental health digital therapeutic products. The current cooperation with Peking University Sixth Hospital and Shandong Mental Health Center further expands the company's footprint in core national psychiatric specialist hospitals, building a three-dimensional commercial implementation network ranging from national flagship centers to regional hubs, and further to key specialist hospitals. The Board believes that the implementation of the aforementioned cooperation agreements and the approval of the key laboratory will further consolidate the company's first-mover advantage in the mental health digital therapy sector, accelerate product R&D and the commercialization process, enhance the company's core position within the "industry-academia-research-medicine" collaborative innovation system, and lay a solid foundation for long-term business development. The company will continue to advance cooperation with other top-tier medical institutions to build a nationwide, integrated industry-academia-research-medicine digital mental health service system.
Comments